The MarketWatch News Department was not involved in the creation of this content. -- Enara's discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically ...
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...
A research team has introduced a novel cancer immunotherapy strategy. This approach involves attaching "fake targets" to tumor cells to guide immune cell attacks, overcoming the limitations of ...
Researchers analyze prostate cancer incidence over 20 years in men aged 45-70 years without prostate cancer and identify ...
Scientists from the Moffitt Cancer Center say they now have a better understanding why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings ...
Researchers from MIT and Dana-Farber Cancer Institute have discovered that a class of peptides expressed in pancreatic cancer cells could be a promising target for T-cell therapies and other ...
Boehringer Ingelheim exercises option to license additional Dark Antigens from a wider array of tumor types, expanding Enara’s eligibility for milestone payments under existing collaboration Scott ...
Enara’s discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically actionable Dark Antigens and will be highlighted in an oral presentation at SITC 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results